Plexxikon Inc.

Rebecca Zuckerman

Prabha N Ibrahim

Chao Zhang

Dean R Artis

Ryan Bremer

Jiazhong Zhang

Hanna Cho

Marika Nespi

Shumeye Mamo

Brian L West

Shenghua Shi

Clarence R Hurt

Gaston G Habets

Sam Gillette

Byunghun Lee

Wayne Spevak

Guoxian Wu

Yong-Liang Zhu

Jack Lin

Heike I Krupka

Hongyao Zhu

Abhinav Kumar

Bruce England

Weiru Wang

Gideon Bollag

Klaus-Peter Hirth

James Tsai

Samuel J Gillette

Jianming Tsai

Yoshihisa Suzuki

Yong Zhu

Yoshisa Suzuki

Helke Krupka

Richard Dean Artis

Gaston Habets

Heike Krupka

Dean Richard Artis

Compounds active on phosphodiesterase PDE4B are provided. Also provided herewith are compositions useful for treatment of PDE4B-mediated diseases or conditions, and methods for the use thereof.

PDE4B inhibitors and uses therefor

Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Compounds and methods for kinase modulation, and indications therefor

Compounds active on Ret are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and structural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate Ret and for identifying improved ligands based on known ligands.

Compounds and methods for development of Ret modulators

Compounds are described that are active on at least one of PPAR&#x3b1;, PPAR&#x3b4;, and PPAR&#x3b3;, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPAR&#x3b1;, PPAR&#x3b4;, and PPAR&#x3b3;, wherein the compounds have the formula: wherein:

PPAR active compounds

Compounds active on the receptor protein tyrosine kinases c-kit and c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or condition and c-fms-mediated diseases or condition, and methods for the use thereof.

Compounds modulating c-kit and c-fms activity and uses therefor

Compounds are described that are active on PDE4. Also described are crystal structures of PDE4B determined using X-ray crystallography, the use of PDE4B crystals and structural information for identifying molecular scaffolds, for developing ligands that bind to and modulate PDE4B, and for identifying improved ligands based on known ligands.

PDE4B inhibitors

Compounds are described that are active on at least one of PPAR&#x3b1;, PPAR&#x3b4;, and PPAR&#x3b3;, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPAR&#x3b1;, PPAR&#x3b4;, and PPAR&#x3b3;.

Growing community of inventors

Alameda, CA, United States of America

Rebecca Zuckerman